论文部分内容阅读
[目的]探讨乳腺癌抗雌激素药物耐药蛋白BCAR1在前列腺癌根治标本中的表达及其临床意义。[方法]应用免疫组化法检测BCAR1在97例前列腺癌根治标本中的表达情况,并分析其在肿瘤组织中的表达与各临床病理因素及预后的相关性。[结果]BCAR1在前列腺高级别上皮内瘤变(HGPIN)和前列腺癌组织中的表达显著高于癌旁前列腺组织(P<0.01)。并且BCAR1在癌组织中高表达与高Gleason评分之间存在显著相关性(χ2=6.987,P=0.008)。但BCAR1的表达与血清PSA水平、肿瘤体积、TNM分期及生物学复发之间均无显著相关性(P>0.05)。[结论 ]BCAR1的表达与前列腺癌的分化程度呈负相关,BCAR1可能在前列腺癌的发生过程中发挥作用。
[Objective] To investigate the expression of breast cancer anti-estrogen drug-resistant protein BCAR1 in radical prostatectomy specimens and its clinical significance. [Method] The expression of BCAR1 in radical prostatectomy of 97 cases of prostate cancer was detected by immunohistochemical method. The correlation between the expression of BCAR1 in clinic and the clinicopathological factors and prognosis was analyzed. [Results] The expression of BCAR1 in high grade intraepithelial neoplasia (HGPIN) and prostate cancer tissues was significantly higher than that in adjacent non-cancerous prostate tissues (P <0.01). There was also a significant correlation between BCAR1 expression in cancerous tissues and high Gleason score (χ2 = 6.987, P = 0.008). However, there was no significant correlation between BCAR1 expression and serum PSA level, tumor volume, TNM stage and biological recurrence (P> 0.05). [Conclusion] The expression of BCAR1 is negatively correlated with the degree of differentiation of prostate cancer. BCAR1 may play a role in the pathogenesis of prostate cancer.